Research: Background and Foundation Flashcards
Can therapy or psychiatry cure any mental health disorders?
Therapy and psychiatry play crucial roles in the treatment and management of mental health disorders, but it’s important to clarify the terminology:
Cure vs. Management: The term “cure” implies the complete and permanent resolution of a condition. Many mental health disorders, especially chronic ones like schizophrenia or bipolar disorder, may not be curable in this strict sense. However, therapy and psychiatric treatments can effectively manage symptoms, improve quality of life, and help individuals lead fulfilling lives despite their conditions.
Therapy: This term usually refers to psychotherapy or talk therapy. Therapy can help individuals understand their conditions, develop coping strategies, and work through traumatic or challenging experiences.
What is psilocybin-assisted therapy and what are its observed effects in clinical trials?
Psilocybin-assisted therapy (Nutt and Carhart-Harris, 2021), involves administering psilocybin in conjunction with psychotherapy.
Clinical trials, as noted by Leger and Unterwald (2022), have shown that this approach can reduce depressive symptoms.
Has there been any research on the worsening of depressive symptoms in psilocybin clinical trials for depression?
To date, no study has specifically evaluated a clinically relevant worsening of depressive symptoms in psilocybin clinical trials for depression, indicating a need for further research in this area.
Is there any information on how baseline demographic characteristics affect the response to psilocybin-assisted therapy?
According to Aday et al. (2021), there is limited information regarding the association of baseline demographic characteristics with symptom worsening or treatment response in psilocybin-assisted therapy.
What were the main findings regarding the effects of a single moderate-dose psilocybin in conjunction with psychotherapy on patients with life-threatening cancer (Ross, 2016) ?
A single moderate dose of psilocybin, used alongside psychotherapy, was found to produce rapid, robust, and sustained reductions in anxiety and depression in patients with life-threatening cancer.
This represents a novel finding in psychiatry, as a single medication dose led to immediate antidepressant and anxiolytic effects with enduring benefits lasting weeks to months.
How long-lasting were the clinical benefits of psilocybin in this context, and what does this imply about its effectiveness (Ross, 2016) ?
The clinical benefits of single-dose psilocybin in reducing cancer-related anxiety and depression appeared to be sustained for more than 7 weeks post-dosing, and possibly as long as 8 months.
This suggests that the effects of psilocybin, when used with psychotherapy, have a significant and prolonged impact on mental health in these patients.
How do the findings of this study compare with previous research on psilocybin’s effects on treatment-resistant depression (TRD) (Ross, 2016)?
The sustained antidepressant effects observed in this study are consistent with those found in a previous study by Carhart-Harris et al. (2016), which reported antidepressant effects of psilocybin in patients with treatment-resistant depression at 1 week and 3 months post-treatment.
What immediate effects were observed after psilocybin administration in both the psilocybin first and niacin first groups (Ross, 2016)?
Both the psilocybin first and niacin first groups showed a marked reduction in anxiety and depression scores immediately after receiving psilocybin. Additionally, the magnitude of change induced by psilocybin was significant across each participant’s active dosing sessions.
What was the antidepressant response rate associated with psilocybin at the 6.5-month follow-up, and how does this compare to traditional antidepressants in treating cancer-related depression?
Psilocybin was associated with high antidepressant response rates, approximately 80% at the 6.5-month follow-up. This contrasts with several meta-analyses of antidepressants for cancer-related depression, which generally have not shown a clear advantage of antidepressant treatment over placebo.
How effective are antidepressants for major depressive disorder in patients with comorbid medical conditions, including cancer?
In a meta-analysis of antidepressants for major depressive disorder in patients with comorbid medical conditions (including cancer), antidepressants were more effective than placebo in some conditions (like HIV/AIDS, post-stroke) but not in cancer patients, where they performed similarly to the approximately 40% placebo response rate.
What secondary outcomes were observed with psilocybin use in cancer patients?
Psilocybin use led to decreased cancer-related demoralization (like loss of meaning, hope, or purpose), reduced hopelessness, and improvements in spiritual well-being, life satisfaction, and quality of life.
Why is addressing existential/spiritual distress important in patients with advanced or terminal cancer, and how might psilocybin help?
Existential/spiritual distress in patients with advanced or terminal cancer, though experienced by a minority, has highly consequential effects like decreased quality of life and increased depressive symptoms. Psilocybin, especially when combined with psychotherapy, could serve as a buffer against these negative outcomes by improving spiritual well-being.
Music and the therapeutic context
In a therapeutic context, psychedelics appear to work in concert with music to enhance emotionality, personal meaning and mental imagery (Kaelen et al., 2017). The interaction between psychedelics and music is believed to be a key component of psychedelics’ therapeutic action (Kaelen et al., 2018).
Music and the therapeutic context in evoking emotions
A significant decrease in music-evoked sadness and a significant increase in music-evoked peacefulness were seen post-treatment with psilocybin.
Our findings of decreased music-evoked ‘sadness’ and increased music-evoked ‘peacefulness’ are consistent with previous studies illustrating the ability of psychedelics to enhance music-evoked emotion (e.g. ‘wonder’ and ‘transcendence’) (Kaelen et al., 2015) and the notion that the combination of music and psychedelics may contribute to the occurrence of mystical-type or peak experiences, which is predictive of the therapeutic effects of psychedelics
Playlist for therapy is essential
Therapy playlist selected based on the Shukuroglou, 2022 study. Reference for therapy sessions.
Jon Hopkins - “Music for Psychedelic Therapy”: A well-known album specifically designed for this purpose.
Steve Roach, Brian Eno, and Max Richter: Artists known for creating ambient and meditative music that’s often used in therapeutic settings.
The “Johns Hopkins Psychedelic Research” playlist on Spotify: A curated playlist often used in clinical psychedelic therapy settings.
What does Delic in the Psychedlic mean?
The word, “Delic” is derived from the Greek word “ Delos” which means to “show or to reveal”.
Using Psilocybin for patients with anxiety and advanced stage cancer.
Life threatening illness comes with existential distress, anxiety, and depression.
A pilot study between 2004- 2008 examined the safety pf psilocybin for advanced stage cancer and anxiety. 12 enrolled patients. Cancer ranging from 2 months - 18 years.
- Anxiety was significantly reduced at the 1 and 3 month follow up.
- Mood improved at 2 weeks follow up.
- Depression symptoms continued to decline.
- The study did not detect large pain reduction perception.
Key phrases during dosing.
Trust, let go, and be open.
Psilocybin and Cancer (NYU Study)
Research found that anxiety and symptoms of depression were significantly reduced after a single dose of psilocybin. These improvements were endured for weeks or months afterwards. 83% of people in the psilocybin condition met the criteria for clinically significant reduction in symptoms. Even after 1 year 60% experinced reduction in depression and 80% reduction in anxiety.
Common patient experiences
From Disconnection to Connection
From avoidance of emotions to acceptance
Preferred to other treatment
Limited side effects, more opportunity for talking, neurochemical change.
Ability to revisit the experience through emotions. Not rushed, giving people time to express feelings.
Psilocybin and nicotine addiction
Research at the John Hopkins University (2013).
Open label psilocybin and 15 week tobacco cessation course . 15 participants
average smoking tie of 31 years
average quit attempts 6 times
4 preparatory sessions with CBT for smoking cessation, 3 psilocybin session, integration sessions weekly.
1st session: Dosage 20 mg/70kg of Psilocybin - Mild dosage.
2nd session (2 weeks later): 30 mg/70kg of Psilocybin.
3rd session (6 weeks later): 30mg/70 kg of Psilocybin.
Procedure same as most psilocybin studies with the addition for the motivational statement to why they are quitting smoking. eg “I want to be clear, clean and healthy”.
They underwent guided imagery exercises during preparatory sessions, after the 1st session and during integration meetings.
Results:
6 month follow up 80% of the participants were abstinent from nicotine for at least the 7 days prior. These rates are much larger than rates reported for approved medications paired with counselling. For example, 6 months the abstinence rate of bupropion was 24.9% and 33.5% for varenicline.
12 months follow up 67% were abstinent from nicotine.
16 months follow up 60% were abstinent from nicotine. Of these 50% said they have not smoked since the very first psilocybin session.
87% of participants rated it among the 10 most meangful experiences of their life.
87& said their personal well-being or life satisfaction had increased very much.
Psilocybin and nicotine addiction - How did the Psilocybin sessions help them quit?
73% - Changing orientation towards the future, so that the long term benefits outweighed immediate desires.
73% - Strengthening participants belief in their ability to quit.
68% - Changing life priorities/ values, such that smoking was no longer more important than quitting.